{"gene":"SLC2A1","run_date":"2026-06-10T07:46:32","timeline":{"discoveries":[{"year":2003,"finding":"GLUT-1 (SLC2A1) is a functional receptor for both HTLV-1 and HTLV-2. The receptor-binding domains of HTLV-1 and HTLV-2 envelope glycoproteins interact with GLUT-1 and inhibit glucose transport. siRNA knockdown of GLUT-1 abrogated HTLV infection, and ectopic expression of GLUT-1 (but not the related GLUT-3) restored infection in GLUT-1-depleted cells.","method":"siRNA knockdown, ectopic overexpression, glucose transport inhibition assay, HTLV envelope-driven infection assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — reciprocal functional rescue experiments, siRNA knockdown, and overexpression with multiple orthogonal readouts in a single rigorous study","pmids":["14622599"],"is_preprint":false},{"year":2001,"finding":"Stomatin (band 7.2b) physically associates with GLUT-1 at the C-terminal 42-amino acid segment of GLUT-1, and overexpression of stomatin reduces GLUT-1 intrinsic transport activity by 35–70% without altering GLUT-1 plasma membrane content, demonstrating that stomatin modulates GLUT-1 activity via protein–protein interaction.","method":"Co-immunoprecipitation, GST pulldown with GLUT-1 C-terminal fusion protein, stable transfection, glucose transport assay","journal":"American Journal of Physiology. Cell Physiology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, GST pulldown mapping to specific GLUT-1 domain, and functional transport assay in a single study","pmids":["11287341"],"is_preprint":false},{"year":2012,"finding":"In human erythrocyte membranes, in situ chemical cross-linking followed by immunoaffinity purification and mass spectrometry identified stomatin, band 3/SLC4A1, and aquaporin-1 as direct interaction partners of GLUT-1, establishing GLUT-1 as a component of a multiprotein membrane complex.","method":"In situ chemical cross-linking, immunoaffinity chromatography, mass spectrometry","journal":"Biochimica et Biophysica Acta","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in situ cross-linking with mass spectrometry identification, single lab but multiple orthogonal biochemical methods","pmids":["23219802"],"is_preprint":false},{"year":1996,"finding":"GLUT-1 interacts with the ER chaperone calnexin (and its soluble homologue calreticulin) in a glycosylation-dependent manner during folding in the endoplasmic reticulum; a non-glycosylated GLUT-1 mutant (AGGT155) failed to associate with either calnexin or calreticulin.","method":"In vitro translation in rabbit reticulocyte lysate with canine pancreatic microsomes, co-immunoprecipitation with anti-calnexin antiserum, UV cross-linking, glycosylation mutant analysis","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with microsomes, UV cross-linking, and glycosylation mutant controls in a single study","pmids":["8662691"],"is_preprint":false},{"year":2013,"finding":"ATM kinase phosphorylates GLUT-1 at serine 490 (S490), and this phosphorylation promotes cell-surface localization of GLUT-1, its interaction with GIPC1 (a recycling endosome protein), and GLUT-1-mediated glucose and dehydroascorbic acid transport in skeletal muscle cells. S490A mutation decreased transport and surface GLUT-1, while S490D mutation increased both.","method":"ATM inhibitor treatment, doxorubicin-mediated ATM activation, S490A and S490D point mutants, cell-surface GLUT-1 measurement, glucose and DHA transport assays, Co-IP of GLUT-1/GIPC1, mouse skeletal muscle ex vivo transport assay","journal":"PloS One","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mutagenesis of the phosphorylation site, pharmacological ATM modulation, functional transport assays, and Co-IP, replicated in cells and mouse tissue","pmids":["23776597"],"is_preprint":false},{"year":2022,"finding":"RAB21 GTPase regulates retromer-mediated recycling of GLUT-1/SLC2A1: RAB21 depletion mis-sorts GLUT-1 to lysosomes, reducing glucose uptake and thereby activating the AMPK-ULK1 autophagy pathway. RAB21 depletion also caused accumulation of the SNX27-containing retromer complex on enlarged endosomes, indicating RAB21 regulates endosomal tubule fission during GLUT-1 recycling.","method":"siRNA knockdown of RAB21, subcellular localization by microscopy, glucose uptake assay, AMPK-ULK1 pathway analysis, immunofluorescence of retromer/SNX27, in vivo tumor xenograft","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined subcellular trafficking phenotype and functional metabolic readout, single lab","pmids":["35993307"],"is_preprint":false},{"year":1999,"finding":"Insulin- and TSH-induced translocation of GLUT-1 from intracellular compartments to the plasma membrane in FRTL-5 thyroid cells is dependent on PI3-kinase activity (blocked by wortmannin and LY294002). TSH/cAMP-driven translocation occurs via a PKA-independent, PI3-kinase-dependent pathway. N-glycosylation of GLUT-1 is required for full transport activity but not for its translocation to the plasma membrane.","method":"PI3-kinase inhibitors (wortmannin, LY294002), PKA inhibitor (H89), tunicamycin (N-glycosylation inhibitor), subcellular fractionation, glucose uptake assay","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors and functional translocation/transport readouts, single lab","pmids":["11089547"],"is_preprint":false},{"year":2001,"finding":"In mesangial cells, GLUT-1 transcription is stimulated by high D-glucose in a manner dependent on glucose metabolism (not the hexose monophosphate shunt). Antisense-mediated reduction of GLUT-1 expression blocks high-glucose-induced upregulation of GLUT-1 and fibronectin expression, demonstrating that GLUT-1-mediated glucose uptake drives a feed-forward loop promoting extracellular matrix production.","method":"Stable antisense GLUT-1 transfection, radiolabeled glucose uptake, GLUT-1 transcription assay, fibronectin mRNA and protein measurement, metabolic substrate substitution experiments","journal":"American Journal of Physiology. Renal Physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined molecular readout, multiple substrates tested, single lab","pmids":["11249857"],"is_preprint":false},{"year":1999,"finding":"The transcription factor Sp1 binds the −102/−82 region of the GLUT-1 promoter and is essential for high transcriptional activity in fetal/neonatal cardiomyocytes; Sp1 is markedly downregulated perinatally in heart and skeletal muscle, explaining the developmental repression of GLUT-1 transcription.","method":"Transient transfection reporter assays, electrophoretic mobility shift assay (EMSA), Sp1 site mutagenesis, developmental Western blot","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — EMSA with site mutagenesis and functional reporter assay, consistent with in vivo developmental expression pattern","pmids":["10364200"],"is_preprint":false},{"year":2001,"finding":"Hyperosmolarity (600 mosmol/L) induces a biphasic increase in GLUT-1-mediated glucose transport: an early phase (0–6 h) independent of changes in GLUT-1 mRNA or protein, and a late phase (12–24 h) driven by increased GLUT-1 mRNA (via both enhanced transcription and mRNA stabilization, half-life increasing from ~2 h to ~8 h) and increased GLUT-1 protein. A 44-bp proximal promoter region is required for basal and hyperosmolarity-induced transcription.","method":"mRNA stability assay, promoter deletion/reporter assay, glucose transport assay, Western blot, GLUT-1 plasma membrane fractionation","journal":"American Journal of Physiology. Cell Physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional promoter dissection, mRNA stability measurement, and transport assay, single lab with multiple orthogonal methods","pmids":["11546675"],"is_preprint":false},{"year":1990,"finding":"Vanadate increases GLUT-1 mRNA expression 4–5-fold in NIH3T3 fibroblasts partly through mRNA stabilization (half-life increased from ~0.5–1 h to ~1.5–2 h), indicating a post-transcriptional regulatory mechanism for GLUT-1 expression.","method":"Northern blot, mRNA half-life determination with actinomycin D chase, glucose transporter functional assay","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mRNA stability assay with single method, single lab","pmids":["2100513"],"is_preprint":false},{"year":2000,"finding":"Heterozygous missense, deletion, insertion, splice-site, and nonsense mutations in GLUT-1/SLC2A1 cause Glut-1 Deficiency Syndrome, characterized by reduced erythrocyte glucose transport activity and hypoglycorrhachia, confirming that GLUT-1 is the essential blood-brain barrier hexose transporter and that single-allele loss is sufficient to impair CNS glucose delivery.","method":"FISH, PCR, SSCP, DNA sequencing, erythrocyte glucose transport activity assay","journal":"Human Mutation","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional transport assay correlated with 15 independent pathogenic mutations, multiple mutation classes, replicated across patients","pmids":["10980529"],"is_preprint":false},{"year":2006,"finding":"Heterozygous targeted disruption of the mouse GLUT-1 gene produces haploinsufficiency phenotype: 66% reduction in brain GLUT-1 protein, reduced brain glucose uptake by PET, hypoglycorrhachia, microencephaly, epileptiform EEG discharges, and impaired motor activity — directly demonstrating that GLUT-1 is the critical blood-brain barrier glucose transporter in vivo.","method":"Targeted gene disruption (homologous recombination), PET imaging, EEG, Western blot, behavioral assays, CSF glucose measurement","journal":"Human Molecular Genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — constitutive KO mouse with multiple orthogonal in vivo phenotypic readouts mirroring human disease","pmids":["16497725"],"is_preprint":false},{"year":2010,"finding":"In vivo knockdown of Glut1 in zebrafish causes loss of cerebral endothelial cells, downregulation of adherens and tight junction proteins, impaired cerebral circulation, and vasogenic brain edema, demonstrating that Glut1 is required for blood-brain barrier development and maintenance of cerebrovascular integrity.","method":"Morpholino-based Glut1 knockdown in zebrafish, live fluorescence imaging, junction protein immunostaining, BBB permeability assay","journal":"Annals of Neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD in zebrafish with defined vascular and molecular phenotypes, single lab","pmids":["21194153"],"is_preprint":false},{"year":2011,"finding":"Mutations in SLC2A1 cause paroxysmal choreoathetosis/spasticity (DYT9), and DYT9 is allelic with DYT18 (paroxysmal exercise-induced dyskinesia); identified mutations reduce glucose uptake in functional assays, confirming causality and expanding the clinical spectrum of GLUT-1 deficiency.","method":"SLC2A1 sequencing, glucose uptake functional assay, cosegregation analysis, absence from 400 control chromosomes","journal":"Neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional glucose uptake assay correlated with mutations in two independent pedigrees, replicated across families","pmids":["21832227"],"is_preprint":false},{"year":2019,"finding":"Myeloid-specific deletion of Slc2a1 (GLUT1) in macrophages blocks glucose uptake and glycolysis, forces metabolic compensation via glutamine and oleate oxidation, blunts maximal respiratory capacity, reduces proinflammatory metabolites, elevates alternative-activation markers (ornithine, polyamines, CD206), and impairs phagocytic capacity — demonstrating that GLUT1 fuels macrophage glycolysis and is required for normal phagocytosis and inflammatory metabolic programming.","method":"Myeloid-specific Cre-lox Slc2a1 knockout, glucose uptake assay, Seahorse metabolic flux analysis, flow cytometry, cytokine measurement, phagocytosis assay, atherosclerosis model","journal":"Journal of Immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — cell-type-specific KO mouse with multiple orthogonal metabolic and functional readouts in vitro and in vivo","pmids":["30659108"],"is_preprint":false},{"year":2000,"finding":"GLUT-1 overexpression in vascular smooth muscle cells reduces hypoxia-induced apoptosis and markedly attenuates hypoxia- and rotenone-induced JNK kinase activation; a catalytically inactive MEKK1 mutant partially phenocopied this protection, placing GLUT-1-dependent glucose uptake upstream of the JNK stress-kinase apoptosis pathway.","method":"Stable GLUT-1 overexpression, hypoxia and rotenone treatment, apoptosis morphology quantification, JNK activity assay, dominant-negative MEKK1 transfection","journal":"American Journal of Physiology. Endocrinology and Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via dominant-negative kinase and GLUT-1 overexpression with defined biochemical pathway readout, single lab","pmids":["10780954"],"is_preprint":false},{"year":2022,"finding":"GLUT-1/SLC2A1 expression is upregulated by hypoxia via HIF-1α stabilization in brain capillary endothelial cells, accompanied by increased [3H]-glucose uptake; stabilizing HIF-1α pharmacologically with desferrioxamine under normoxia mimics this effect, establishing HIF-1α as the transcriptional regulator of GLUT-1 upregulation in BBB endothelium under hypoxia.","method":"Primary bovine brain capillary endothelial cell culture under hypoxia, HIF-1α immunocytochemistry/confocal imaging, qPCR, Western blot, [3H]-glucose uptake assay, desferrioxamine (DFO) pharmacological HIF-1α stabilization","journal":"Fluids and Barriers of the CNS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological HIF-1α stabilization mimicking hypoxia with functional transport readout, single lab, multiple methods","pmids":["34983574"],"is_preprint":false},{"year":2018,"finding":"miR-328 directly targets the 3′-UTR of SLC2A1/GLUT1 mRNA (confirmed by luciferase reporter assay) and suppresses GLUT1 protein expression in colon cancer cells, reducing glycolysis.","method":"Luciferase reporter assay with SLC2A1 3′-UTR, Western blot, miR-328 overexpression in colon cancer cell lines","journal":"Clinical & Translational Oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter and Western blot confirmation, single lab, two cell lines","pmids":["29374351"],"is_preprint":false},{"year":2017,"finding":"miR-148b directly targets SLC2A1/GLUT1 3′-UTR (luciferase assay), suppresses GLUT1 protein, and limits glycolysis (glucose consumption, lactate production) in gastric cancer cells; GLUT1 overexpression rescued glycolysis suppressed by miR-148b, establishing direct miR-148b → GLUT1 → glycolysis regulation.","method":"Luciferase 3′-UTR reporter assay, Western blot, siRNA, GLUT1 overexpression rescue, glucose/lactate metabolic assays","journal":"Cancer Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase, rescue experiment, and functional metabolic assay, single lab","pmids":["28440026"],"is_preprint":false},{"year":2022,"finding":"Isoginkgetin (ISO) suppresses SLC2A1/GLUT1 enhancer activity (reducing H3K27ac, H4K8ac, and H3K4me1 marks on the GLUT1 enhancer) by binding to and promoting degradation of CDK6; CDK6 overexpression rescued GLUT1 transcription and autophagy suppression, placing CDK6 upstream of GLUT1 enhancer activity in HCC.","method":"Molecular docking, thermal shift analysis, CDK6 overexpression rescue, ChIP for histone marks at SLC2A1 enhancer, glucose uptake assay, AMPK-ULK1 pathway analysis, xenograft","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct CDK6 binding confirmed by thermal shift, ChIP mapping to GLUT1 enhancer, genetic rescue, single lab","pmids":["36048765"],"is_preprint":false},{"year":1994,"finding":"Transgenic overexpression of GLUT-1 in skeletal muscle paradoxically reduces insulin-stimulated whole-body glucose disposal (GIR 54% of controls) and induces marked hyperketonemia, whereas GLUT-4 overexpression enhances insulin-stimulated glucose disposal — demonstrating that the identity (not merely level) of glucose transporter isoform critically shapes whole-body insulin responsiveness.","method":"Euglycemic hyperinsulinemic clamp in transgenic mice overexpressing GLUT-1 or GLUT-4, glucose infusion rate measurement, β-hydroxybutyrate measurement","journal":"The American Journal of Physiology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo metabolic clamp in two independent transgenic mouse lines with direct comparison of GLUT-1 vs GLUT-4 isoform-specific effects","pmids":["7977725"],"is_preprint":false},{"year":2012,"finding":"SLC2A1 trinucleotide deletion (deleting isoleucine 435 or 436) causes a cation-leaky GLUT-1 variant that constitutively allows monovalent cation (Na+/K+) permeation across the red cell membrane, in addition to abrogating glucose transport — demonstrating that single residues in the GLUT-1 transmembrane domain determine both substrate selectivity and cation permeability.","method":"SLC2A1 sequencing, red cell cation content measurement, temperature-dependent K+ loss assay, clinical phenotyping","journal":"The Journal of Clinical Endocrinology and Metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — functional red cell transport assay with identified mutation, single case/family","pmids":["22492876"],"is_preprint":false},{"year":2017,"finding":"GLUT-1/SLC2A1 siRNA intravitreal injection in diabetic mice reduces retinal glucose concentration, ICAM-1 and TNF-α expression, leukostasis, and vascular leakage — establishing that GLUT-1-mediated glucose transport into the retina is a causal driver of the inflammatory microangiopathy of diabetic retinopathy.","method":"Intravitreal siRNA injection in streptozotocin-diabetic mice, retinal glucose assay, ERG, immunoblotting for ICAM-1/TNF-α, leukostasis assay, Evans blue vascular permeability assay","journal":"Scientific Reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo siRNA KD with multiple mechanistic readouts, single lab","pmids":["28785055"],"is_preprint":false}],"current_model":"SLC2A1/GLUT-1 is a 12-transmembrane-domain facilitative glucose transporter that mediates constitutive glucose uptake across the plasma membrane; its transport activity is modulated by stomatin (via direct C-terminal protein–protein interaction), by ATM-mediated phosphorylation at S490 (which promotes surface localization via GIPC1-dependent recycling), and by retromer/RAB21-dependent endosomal recycling; its transcription is driven by Sp1 in cardiomyocytes and by HIF-1α under hypoxia, and its mRNA is stabilized by osmotic and metabolic stress; it serves as the obligate HTLV receptor, is essential for blood-brain barrier development and glucose delivery to the CNS (haploinsufficiency causing seizures, hypoglycorrhachia, and microcephaly), and fuels macrophage glycolysis required for normal phagocytic and inflammatory function."},"narrative":{"mechanistic_narrative":"SLC2A1/GLUT-1 is the constitutive facilitative glucose transporter that delivers glucose across the plasma membrane to fuel cellular metabolism, and it is the obligate hexose transporter of the blood-brain barrier [PMID:10980529, PMID:16497725]. Its substrate selectivity and cation impermeability are determined by individual transmembrane residues, with isoleucine deletions in the transmembrane domain both abrogating glucose transport and creating a cation-leaky channel [PMID:22492876]. Transport activity is set not only by surface abundance but by direct protein-protein modulation: stomatin binds the GLUT-1 C-terminal 42-residue segment and suppresses intrinsic transport activity without changing membrane content, and GLUT-1 functions within a multiprotein erythrocyte membrane complex with stomatin, band 3/SLC4A1, and aquaporin-1 [PMID:11287341, PMID:23219802]. Surface delivery is governed by trafficking: N-glycosylation-dependent folding under calnexin/calreticulin in the ER [PMID:8662691], PI3-kinase-dependent insulin/TSH-induced translocation [PMID:11089547], ATM-mediated phosphorylation at S490 that drives GIPC1-dependent recycling endosome surface localization [PMID:23776597], and RAB21/retromer-dependent endosomal recycling that prevents lysosomal mis-sorting and thereby restrains AMPK-ULK1 autophagy [PMID:35993307]. GLUT-1 transcription is driven by Sp1 in developing cardiomyocytes [PMID:10364200] and by HIF-1α under hypoxia [PMID:34983574], while its mRNA is stabilized by osmotic and metabolic stress [PMID:11546675, PMID:2100513] and repressed post-transcriptionally by microRNAs targeting its 3'-UTR [PMID:29374351, PMID:28440026]. Functionally, GLUT-1-mediated glucose uptake fuels macrophage glycolysis required for phagocytosis and inflammatory metabolic programming [PMID:30659108], drives feed-forward extracellular matrix production in mesangial cells [PMID:11249857], and protects against hypoxic apoptosis upstream of JNK stress signaling [PMID:10780954]. Heterozygous loss-of-function mutations cause GLUT-1 Deficiency Syndrome with hypoglycorrhachia, seizures, and microcephaly, and allelic mutations cause paroxysmal exercise-induced dyskinesia (DYT9/DYT18) [PMID:10980529, PMID:21832227]. GLUT-1 also serves as the functional receptor for HTLV-1 and HTLV-2 [PMID:14622599].","teleology":[{"year":1990,"claim":"Established that GLUT-1 expression is regulated post-transcriptionally, addressing whether transporter abundance is controlled beyond transcription.","evidence":"Vanadate-induced mRNA half-life measurement by actinomycin D chase and Northern blot in NIH3T3 fibroblasts","pmids":["2100513"],"confidence":"Medium","gaps":["The trans-acting factor or 3'-UTR element mediating stabilization was not identified","Single stimulus and single cell type"]},{"year":1994,"claim":"Showed that glucose transporter isoform identity, not just transport capacity, shapes whole-body insulin responsiveness, distinguishing GLUT-1 from insulin-responsive GLUT-4.","evidence":"Euglycemic hyperinsulinemic clamp in transgenic mice overexpressing GLUT-1 versus GLUT-4 in skeletal muscle","pmids":["7977725"],"confidence":"High","gaps":["Mechanism for paradoxical reduction in insulin-stimulated disposal and hyperketonemia not resolved","Does not address endogenous GLUT-1 physiology"]},{"year":1996,"claim":"Defined the biogenesis route of GLUT-1, showing glycosylation-dependent ER chaperone engagement governs folding before surface delivery.","evidence":"In vitro translation with pancreatic microsomes, anti-calnexin Co-IP, UV cross-linking, and a non-glycosylated AGGT155 mutant","pmids":["8662691"],"confidence":"High","gaps":["Downstream quality-control fate of misfolded GLUT-1 not characterized","In vitro reconstitution only"]},{"year":1999,"claim":"Identified Sp1 as the transcriptional driver of GLUT-1 in heart and linked perinatal Sp1 loss to developmental repression of the gene.","evidence":"Reporter assays, EMSA with Sp1 site mutagenesis, and developmental Western blot in cardiomyocytes","pmids":["10364200"],"confidence":"High","gaps":["Cofactors at the Sp1 site not defined","Restricted to cardiac/skeletal muscle context"]},{"year":1999,"claim":"Resolved the signaling route for stimulus-induced GLUT-1 surface translocation, showing it is PI3-kinase-dependent and PKA-independent.","evidence":"Pharmacological dissection with wortmannin, LY294002, H89, and tunicamycin plus subcellular fractionation in FRTL-5 thyroid cells","pmids":["11089547"],"confidence":"Medium","gaps":["Vesicle machinery downstream of PI3K not identified","Pharmacological inhibitors lack target specificity"]},{"year":2000,"claim":"Confirmed in vivo that single-allele GLUT-1 mutations are sufficient to impair CNS glucose delivery, establishing GLUT-1 as the essential blood-brain barrier hexose transporter and defining GLUT-1 Deficiency Syndrome.","evidence":"Mutation screening across multiple patients correlated with erythrocyte glucose transport assays","pmids":["10980529"],"confidence":"High","gaps":["Genotype-phenotype severity correlation not fully resolved","Does not address tissue-specific dosage thresholds"]},{"year":2000,"claim":"Placed GLUT-1-dependent glucose uptake upstream of the JNK stress-kinase apoptosis pathway, linking the transporter to cell survival under hypoxia.","evidence":"GLUT-1 overexpression with hypoxia/rotenone challenge, JNK activity assay, and dominant-negative MEKK1 epistasis in vascular smooth muscle cells","pmids":["10780954"],"confidence":"Medium","gaps":["Metabolic signal connecting glucose uptake to JNK suppression not defined","Overexpression rather than endogenous regulation"]},{"year":2001,"claim":"Demonstrated direct protein-protein modulation of GLUT-1 transport activity by stomatin, independent of surface abundance.","evidence":"Co-IP, GST pulldown mapping to the GLUT-1 C-terminal 42 residues, and glucose transport assay in transfected cells","pmids":["11287341"],"confidence":"High","gaps":["Structural basis of the C-terminal interaction not solved","Mechanism by which binding lowers intrinsic activity unknown"]},{"year":2001,"claim":"Showed GLUT-1-mediated glucose uptake drives a feed-forward loop promoting extracellular matrix production, linking the transporter to diabetic glomerular pathology.","evidence":"Antisense GLUT-1 knockdown with fibronectin readout and metabolic substrate substitution in mesangial cells","pmids":["11249857"],"confidence":"Medium","gaps":["Metabolic signal coupling glucose flux to fibronectin transcription not identified","Single cell type"]},{"year":2001,"claim":"Defined a biphasic GLUT-1 response to osmotic stress combining transcriptional induction and mRNA stabilization, mapping a 44-bp proximal promoter element.","evidence":"mRNA stability assay, promoter deletion reporters, transport assay, and membrane fractionation under hyperosmolarity","pmids":["11546675"],"confidence":"Medium","gaps":["The factor mediating mRNA stabilization not identified","Early phase mechanism (non-transcriptional, non-translocation) unexplained"]},{"year":2003,"claim":"Identified GLUT-1 as the obligate functional receptor for HTLV-1 and HTLV-2, with envelope binding directly inhibiting glucose transport.","evidence":"siRNA knockdown, ectopic GLUT-1 versus GLUT-3 rescue, glucose transport inhibition, and infection assays","pmids":["14622599"],"confidence":"High","gaps":["The GLUT-1 binding interface for envelope glycoprotein not mapped","Whether transport inhibition is mechanistically required for entry not resolved"]},{"year":2006,"claim":"Recapitulated GLUT-1 Deficiency Syndrome in vivo, directly demonstrating that GLUT-1 haploinsufficiency reduces brain glucose uptake and causes the seizure/microcephaly phenotype.","evidence":"Heterozygous GLUT-1 knockout mouse with PET, EEG, CSF glucose, Western blot, and behavioral assays","pmids":["16497725"],"confidence":"High","gaps":["Cellular site of critical dosage sensitivity (endothelium vs glia vs neuron) not isolated","Developmental timing of irreversible injury not defined"]},{"year":2010,"claim":"Established a developmental and structural role for GLUT-1 in blood-brain barrier formation beyond simple glucose delivery, showing it is required for cerebral endothelial integrity.","evidence":"Morpholino Glut1 knockdown in zebrafish with junction protein immunostaining and BBB permeability assays","pmids":["21194153"],"confidence":"Medium","gaps":["Whether the vascular defect is secondary to metabolic deficit or a distinct function unclear","Morpholino off-target effects not fully excluded"]},{"year":2011,"claim":"Expanded the GLUT-1 deficiency phenotypic spectrum to paroxysmal dyskinesia, showing DYT9 is allelic with DYT18 and that the mutations reduce glucose uptake.","evidence":"SLC2A1 sequencing, cosegregation, control screening, and glucose uptake functional assays in two pedigrees","pmids":["21832227"],"confidence":"High","gaps":["Why partial loss yields paroxysmal rather than constant phenotype not explained","Genotype-phenotype determinants across the spectrum unresolved"]},{"year":2012,"claim":"Defined the native GLUT-1 membrane complex partners in erythrocytes, situating the transporter within a multiprotein assembly.","evidence":"In situ chemical cross-linking, immunoaffinity purification, and mass spectrometry of erythrocyte membranes","pmids":["23219802"],"confidence":"High","gaps":["Functional consequence of band 3 and aquaporin-1 association not tested","Stoichiometry and architecture of the complex unknown"]},{"year":2012,"claim":"Showed that single transmembrane residues govern both glucose selectivity and cation impermeability, as an isoleucine deletion creates a cation-leaky GLUT-1.","evidence":"SLC2A1 sequencing with red cell cation content and temperature-dependent K+ loss assays","pmids":["22492876"],"confidence":"Medium","gaps":["Single family; structural mechanism of the cation leak not modeled","Relationship between leak and clinical phenotype not fully defined"]},{"year":2013,"claim":"Identified ATM-mediated S490 phosphorylation as a regulatory switch driving GLUT-1 surface localization through GIPC1-dependent recycling.","evidence":"S490A/S490D mutants, pharmacological ATM modulation, GLUT-1/GIPC1 Co-IP, and transport assays in cells and mouse muscle","pmids":["23776597"],"confidence":"High","gaps":["Physiological signal activating ATM-GLUT-1 phosphorylation in muscle not defined","How GIPC1 engagement directs recycling mechanistically unclear"]},{"year":2017,"claim":"Demonstrated microRNA control of GLUT-1, with miR-148b directly targeting the 3'-UTR to limit glycolysis in cancer cells.","evidence":"Luciferase 3'-UTR reporter, Western blot, siRNA, GLUT1 overexpression rescue, and glucose/lactate assays in gastric cancer cells","pmids":["28440026"],"confidence":"Medium","gaps":["In vivo relevance of the miR-148b axis not established","Single cancer context"]},{"year":2017,"claim":"Established GLUT-1-mediated retinal glucose transport as a causal driver of diabetic inflammatory microangiopathy.","evidence":"Intravitreal GLUT-1 siRNA in diabetic mice with retinal glucose, ICAM-1/TNF-α, leukostasis, and vascular permeability readouts","pmids":["28785055"],"confidence":"Medium","gaps":["Cell type within retina mediating the effect not isolated","Single lab in vivo model"]},{"year":2018,"claim":"Added a second microRNA, miR-328, directly repressing GLUT1 via its 3'-UTR to reduce glycolysis in colon cancer.","evidence":"Luciferase reporter with SLC2A1 3'-UTR, Western blot, and miR-328 overexpression in colon cancer cell lines","pmids":["29374351"],"confidence":"Medium","gaps":["Functional metabolic rescue not shown as definitively as for miR-148b","No in vivo validation"]},{"year":2019,"claim":"Defined GLUT1 as the essential fuel source for macrophage glycolysis, required for phagocytosis and inflammatory metabolic programming.","evidence":"Myeloid-specific Slc2a1 knockout with Seahorse flux, metabolite profiling, flow cytometry, phagocytosis, and atherosclerosis modeling","pmids":["30659108"],"confidence":"High","gaps":["Whether glycolytic versus non-metabolic functions drive the phenotype not fully separated","Compensatory glutamine/oleate pathways not therapeutically tested"]},{"year":2022,"claim":"Identified RAB21-controlled retromer recycling as essential for keeping GLUT-1 at the surface, with disruption mis-sorting it to lysosomes and activating autophagy.","evidence":"RAB21 siRNA, microscopy of GLUT-1 and SNX27 retromer, glucose uptake, AMPK-ULK1 analysis, and tumor xenograft","pmids":["35993307"],"confidence":"Medium","gaps":["Direct RAB21-GLUT-1 versus indirect retromer effect not separated","Single lab"]},{"year":2022,"claim":"Established HIF-1α as the transcriptional driver of GLUT-1 induction in blood-brain barrier endothelium under hypoxia.","evidence":"Hypoxia and desferrioxamine HIF-1α stabilization in brain capillary endothelial cells with glucose uptake, qPCR, and Western blot","pmids":["34983574"],"confidence":"Medium","gaps":["Direct HIF-1α occupancy of the SLC2A1 promoter not shown here","Primary culture model only"]},{"year":2022,"claim":"Linked CDK6 to GLUT1 enhancer activity, showing CDK6 maintains active histone marks that drive GLUT1 transcription in hepatocellular carcinoma.","evidence":"Isoginkgetin-induced CDK6 degradation, thermal shift binding, CDK6 rescue, ChIP of enhancer histone marks, glucose uptake, and xenograft","pmids":["36048765"],"confidence":"Medium","gaps":["How CDK6 mechanistically promotes enhancer acetylation/methylation not defined","Restricted to HCC context"]},{"year":null,"claim":"How the diverse transcriptional (Sp1, HIF-1α, CDK6), post-transcriptional (mRNA stabilization, microRNAs), and trafficking (calnexin, PI3K, ATM/GIPC1, RAB21/retromer, stomatin) regulatory layers are integrated to set GLUT-1 surface activity in a given tissue remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model connecting trafficking control to transcriptional control","Structural basis of substrate selectivity and cation gating not resolved in the corpus","Tissue-specific dosage thresholds underlying disease severity not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[11,12,14,22]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[0]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,6]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[11,12,15]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[15,7]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[5,20]}],"complexes":["erythrocyte GLUT-1/stomatin/band 3/aquaporin-1 membrane complex"],"partners":["STOM","SLC4A1","AQP1","CANX","CALR","GIPC1","RAB21"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11166","full_name":"Solute carrier family 2, facilitated glucose transporter member 1","aliases":["Glucose transporter type 1, erythrocyte/brain","GLUT-1","HepG2 glucose transporter"],"length_aa":492,"mass_kda":54.1,"function":"Facilitative glucose transporter, which is responsible for constitutive or basal glucose uptake (PubMed:10227690, PubMed:10954735, PubMed:18245775, PubMed:19449892, PubMed:25982116, PubMed:27078104, PubMed:32860739). Has a very broad substrate specificity; can transport a wide range of aldoses including both pentoses and hexoses (PubMed:18245775, PubMed:19449892). Most important energy carrier of the brain: present at the blood-brain barrier and assures the energy-independent, facilitative transport of glucose into the brain (PubMed:10227690). In association with BSG and NXNL1, promotes retinal cone survival by increasing glucose uptake into photoreceptors (By similarity). Required for mesendoderm differentiation (By similarity)","subcellular_location":"Cell membrane; Melanosome; Photoreceptor inner segment","url":"https://www.uniprot.org/uniprotkb/P11166/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SLC2A1","classification":"Not Classified","n_dependent_lines":527,"n_total_lines":1208,"dependency_fraction":0.43625827814569534},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000117394","cell_line_id":"CID001326","localizations":[{"compartment":"vesicles","grade":3}],"interactors":[{"gene":"HSP90AB1","stoichiometry":0.2},{"gene":"HSP90AB2P","stoichiometry":0.2},{"gene":"VAMP3","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001326","total_profiled":1310},"omim":[{"mim_id":"617447","title":"PABP-DEPENDENT POLY(A) NUCLEASE 2; PAN2","url":"https://www.omim.org/entry/617447"},{"mim_id":"616158","title":"NEURODEVELOPMENTAL DISORDER WITH NEONATAL RESPIRATORY INSUFFICIENCY, HYPOTONIA, AND FEEDING DIFFICULTIES; NEDRIHF","url":"https://www.omim.org/entry/616158"},{"mim_id":"615603","title":"CALCINEURIN-LIKE PHOSPHOESTERASE DOMAIN-CONTAINING PROTEIN 1; CPPED1","url":"https://www.omim.org/entry/615603"},{"mim_id":"615227","title":"COMPLEMENT COMPONENT 1, q SUBCOMPONENT-LIKE 3; C1QL3","url":"https://www.omim.org/entry/615227"},{"mim_id":"614847","title":"EPILEPSY, IDIOPATHIC GENERALIZED, SUSCEPTIBILITY TO, 12; EIG12","url":"https://www.omim.org/entry/614847"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Plasma membrane","reliability":"Enhanced"},{"location":"Centriolar satellite","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":92.7}],"url":"https://www.proteinatlas.org/search/SLC2A1"},"hgnc":{"alias_symbol":["DYT18","DYT9","GLUT-1"],"prev_symbol":["GLUT1","GLUT","HTLVR","CSE"]},"alphafold":{"accession":"P11166","domains":[{"cath_id":"1.20.1250.20","chopping":"10-207","consensus_level":"medium","plddt":95.4507,"start":10,"end":207},{"cath_id":"1.20.1250.20","chopping":"257-470","consensus_level":"medium","plddt":90.6369,"start":257,"end":470}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11166","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11166-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11166-F1-predicted_aligned_error_v6.png","plddt_mean":90.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SLC2A1","jax_strain_url":"https://www.jax.org/strain/search?query=SLC2A1"},"sequence":{"accession":"P11166","fasta_url":"https://rest.uniprot.org/uniprotkb/P11166.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11166/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11166"}},"corpus_meta":[{"pmid":"23506862","id":"PMC_23506862","title":"The SLC2 (GLUT) family of membrane transporters.","date":"2013","source":"Molecular aspects of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23506862","citation_count":975,"is_preprint":false},{"pmid":"15389572","id":"PMC_15389572","title":"Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer.","date":"2005","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15389572","citation_count":960,"is_preprint":false},{"pmid":"12568659","id":"PMC_12568659","title":"Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.","date":"2003","source":"The British journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/12568659","citation_count":613,"is_preprint":false},{"pmid":"14622599","id":"PMC_14622599","title":"The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV.","date":"2003","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/14622599","citation_count":328,"is_preprint":false},{"pmid":"12532423","id":"PMC_12532423","title":"GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding.","date":"2003","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12532423","citation_count":187,"is_preprint":false},{"pmid":"9390772","id":"PMC_9390772","title":"GLUT-1 expression in the cerebra of patients with Alzheimer's disease.","date":"1997","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/9390772","citation_count":167,"is_preprint":false},{"pmid":"31324056","id":"PMC_31324056","title":"Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31324056","citation_count":160,"is_preprint":false},{"pmid":"16497725","id":"PMC_16497725","title":"A mouse model for Glut-1 haploinsufficiency.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16497725","citation_count":156,"is_preprint":false},{"pmid":"11571727","id":"PMC_11571727","title":"GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy.","date":"2001","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11571727","citation_count":146,"is_preprint":false},{"pmid":"24578007","id":"PMC_24578007","title":"Correlation of Glut-1 glucose transporter expression with [(18)F]FDG uptake in non-small cell lung cancer.","date":"2000","source":"European journal of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24578007","citation_count":146,"is_preprint":false},{"pmid":"9776278","id":"PMC_9776278","title":"FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.","date":"1998","source":"Journal of nuclear medicine : official publication, Society of Nuclear Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9776278","citation_count":138,"is_preprint":false},{"pmid":"9914598","id":"PMC_9914598","title":"Placental glucose transport and GLUT 1 expression in insulin-dependent diabetes.","date":"1999","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/9914598","citation_count":122,"is_preprint":false},{"pmid":"12031879","id":"PMC_12031879","title":"Expression of hexokinase II and Glut-1 in untreated human breast cancer.","date":"2002","source":"Nuclear medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/12031879","citation_count":119,"is_preprint":false},{"pmid":"10980529","id":"PMC_10980529","title":"Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome.","date":"2000","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/10980529","citation_count":115,"is_preprint":false},{"pmid":"30659108","id":"PMC_30659108","title":"Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30659108","citation_count":110,"is_preprint":false},{"pmid":"21194153","id":"PMC_21194153","title":"Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21194153","citation_count":97,"is_preprint":false},{"pmid":"10484371","id":"PMC_10484371","title":"GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity.","date":"1999","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10484371","citation_count":92,"is_preprint":false},{"pmid":"11287341","id":"PMC_11287341","title":"Overexpression of stomatin depresses GLUT-1 glucose transporter activity.","date":"2001","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11287341","citation_count":91,"is_preprint":false},{"pmid":"16426919","id":"PMC_16426919","title":"The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis.","date":"2005","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16426919","citation_count":88,"is_preprint":false},{"pmid":"25132463","id":"PMC_25132463","title":"Increased glucose and placental GLUT-1 in large infants of obese nondiabetic mothers.","date":"2014","source":"American journal of obstetrics and gynecology","url":"https://pubmed.ncbi.nlm.nih.gov/25132463","citation_count":82,"is_preprint":false},{"pmid":"21938742","id":"PMC_21938742","title":"Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.","date":"2012","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21938742","citation_count":82,"is_preprint":false},{"pmid":"32174012","id":"PMC_32174012","title":"Long noncoding RNA SLC2A1-AS1 regulates aerobic glycolysis and progression in hepatocellular carcinoma via inhibiting the STAT3/FOXM1/GLUT1 pathway.","date":"2020","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32174012","citation_count":80,"is_preprint":false},{"pmid":"32352752","id":"PMC_32352752","title":"GLUT-1: An Effective Target To Deliver Brain-Derived Neurotrophic Factor Gene Across the Blood Brain Barrier.","date":"2020","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32352752","citation_count":77,"is_preprint":false},{"pmid":"1512261","id":"PMC_1512261","title":"Expression and function of GLUT-1 and GLUT-2 glucose transporter isoforms in cells of cultured rat pancreatic islets.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1512261","citation_count":76,"is_preprint":false},{"pmid":"10780954","id":"PMC_10780954","title":"GLUT-1 reduces hypoxia-induced apoptosis and JNK pathway activation.","date":"2000","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10780954","citation_count":74,"is_preprint":false},{"pmid":"15515055","id":"PMC_15515055","title":"Oxygen-regulated expression of GLUT-1, GLUT-3, and VEGF in the mouse blastocyst.","date":"2005","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/15515055","citation_count":74,"is_preprint":false},{"pmid":"22190995","id":"PMC_22190995","title":"Glut-1 Expression Correlates with Basal-like Breast Cancer.","date":"2011","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/22190995","citation_count":73,"is_preprint":false},{"pmid":"31469221","id":"PMC_31469221","title":"Synthesis of Indomorphan Pseudo-Natural Product Inhibitors of Glucose Transporters GLUT-1 and -3.","date":"2019","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/31469221","citation_count":72,"is_preprint":false},{"pmid":"22681646","id":"PMC_22681646","title":"GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle.","date":"2012","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/22681646","citation_count":70,"is_preprint":false},{"pmid":"15517916","id":"PMC_15517916","title":"Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma.","date":"2004","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15517916","citation_count":70,"is_preprint":false},{"pmid":"21832227","id":"PMC_21832227","title":"Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect.","date":"2011","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21832227","citation_count":69,"is_preprint":false},{"pmid":"12771048","id":"PMC_12771048","title":"GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury?","date":"2003","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/12771048","citation_count":69,"is_preprint":false},{"pmid":"23219802","id":"PMC_23219802","title":"Stomatin interacts with GLUT1/SLC2A1, band 3/SLC4A1, and aquaporin-1 in human erythrocyte membrane domains.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23219802","citation_count":68,"is_preprint":false},{"pmid":"18620729","id":"PMC_18620729","title":"GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms.","date":"2008","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18620729","citation_count":65,"is_preprint":false},{"pmid":"10582549","id":"PMC_10582549","title":"Functional electrical stimulation exercise increases GLUT-1 and GLUT-4 in paralyzed skeletal muscle.","date":"1999","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/10582549","citation_count":64,"is_preprint":false},{"pmid":"7977725","id":"PMC_7977725","title":"Differential effects of GLUT-1 or GLUT-4 overexpression on insulin responsiveness in transgenic mice.","date":"1994","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/7977725","citation_count":62,"is_preprint":false},{"pmid":"8638693","id":"PMC_8638693","title":"Increments in skeletal muscle GLUT-1 and GLUT-4 after endurance training in humans.","date":"1996","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8638693","citation_count":62,"is_preprint":false},{"pmid":"9530136","id":"PMC_9530136","title":"Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effects of cell activation.","date":"1998","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9530136","citation_count":61,"is_preprint":false},{"pmid":"11006027","id":"PMC_11006027","title":"Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary.","date":"2000","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11006027","citation_count":58,"is_preprint":false},{"pmid":"16142350","id":"PMC_16142350","title":"Expression of HIF-1alpha and Glut-1 in human bladder cancer.","date":"2005","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/16142350","citation_count":57,"is_preprint":false},{"pmid":"28623979","id":"PMC_28623979","title":"Placental glucose transporter (GLUT)-1 is down-regulated in preeclampsia.","date":"2017","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/28623979","citation_count":56,"is_preprint":false},{"pmid":"11089547","id":"PMC_11089547","title":"Glut-1 translocation in FRTL-5 thyroid cells: role of phosphatidylinositol 3-kinase and N-glycosylation.","date":"2000","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11089547","citation_count":55,"is_preprint":false},{"pmid":"26238658","id":"PMC_26238658","title":"Inhibiting GLUT-1 expression and PI3K/Akt signaling using apigenin improves the radiosensitivity of laryngeal carcinoma in vivo.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/26238658","citation_count":53,"is_preprint":false},{"pmid":"36048765","id":"PMC_36048765","title":"Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/36048765","citation_count":49,"is_preprint":false},{"pmid":"25120770","id":"PMC_25120770","title":"Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study.","date":"2014","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25120770","citation_count":49,"is_preprint":false},{"pmid":"19289587","id":"PMC_19289587","title":"Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.","date":"2009","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19289587","citation_count":44,"is_preprint":false},{"pmid":"8662691","id":"PMC_8662691","title":"The glut 1 glucose transporter interacts with calnexin and calreticulin.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8662691","citation_count":43,"is_preprint":false},{"pmid":"31105886","id":"PMC_31105886","title":"Roles of GLUT-1 and HK-II expression in the biological behavior of head and neck cancer.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/31105886","citation_count":43,"is_preprint":false},{"pmid":"23108021","id":"PMC_23108021","title":"IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.","date":"2013","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/23108021","citation_count":43,"is_preprint":false},{"pmid":"28785055","id":"PMC_28785055","title":"Suppression of diabetic retinopathy with GLUT1 siRNA.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28785055","citation_count":41,"is_preprint":false},{"pmid":"10364200","id":"PMC_10364200","title":"Factors involved in GLUT-1 glucose transporter gene transcription in cardiac muscle.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10364200","citation_count":41,"is_preprint":false},{"pmid":"34983574","id":"PMC_34983574","title":"Hypoxia increases expression of selected blood-brain barrier transporters GLUT-1, P-gp, SLC7A5 and TFRC, while maintaining barrier integrity, in brain capillary endothelial monolayers.","date":"2022","source":"Fluids and barriers of the CNS","url":"https://pubmed.ncbi.nlm.nih.gov/34983574","citation_count":41,"is_preprint":false},{"pmid":"32556218","id":"PMC_32556218","title":"Steroids Regulate SLC2A1 and SLC2A3 to Deliver Glucose Into Trophectoderm for Metabolism via Glycolysis.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32556218","citation_count":40,"is_preprint":false},{"pmid":"29374351","id":"PMC_29374351","title":"miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1.","date":"2018","source":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","url":"https://pubmed.ncbi.nlm.nih.gov/29374351","citation_count":40,"is_preprint":false},{"pmid":"30464533","id":"PMC_30464533","title":"Inhibition of GLUT-1 expression and the PI3K/Akt pathway to enhance the chemosensitivity of laryngeal carcinoma cells in vitro.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30464533","citation_count":39,"is_preprint":false},{"pmid":"8761487","id":"PMC_8761487","title":"Regulation of glucose transporters (GLUT-1 and GLUT-3) in human retinal endothelial cells.","date":"1996","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/8761487","citation_count":38,"is_preprint":false},{"pmid":"28440026","id":"PMC_28440026","title":"miR-148b inhibits glycolysis in gastric cancer through targeting SLC2A1.","date":"2017","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28440026","citation_count":38,"is_preprint":false},{"pmid":"11249857","id":"PMC_11249857","title":"Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin expression.","date":"2001","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11249857","citation_count":38,"is_preprint":false},{"pmid":"25932183","id":"PMC_25932183","title":"Inhibition of glucose-transporter 1 (GLUT-1) expression reversed Warburg effect in gastric cancer cell MKN45.","date":"2015","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25932183","citation_count":37,"is_preprint":false},{"pmid":"23776597","id":"PMC_23776597","title":"ATM and GLUT1-S490 phosphorylation regulate GLUT1 mediated transport in skeletal muscle.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23776597","citation_count":36,"is_preprint":false},{"pmid":"35993307","id":"PMC_35993307","title":"RAB21 controls autophagy and cellular energy homeostasis by regulating retromer-mediated recycling of SLC2A1/GLUT1.","date":"2022","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/35993307","citation_count":35,"is_preprint":false},{"pmid":"34070830","id":"PMC_34070830","title":"GLUT-1 Enhances Glycolysis, Oxidative Stress, and Fibroblast Proliferation in Keloid.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34070830","citation_count":35,"is_preprint":false},{"pmid":"26062860","id":"PMC_26062860","title":"GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma.","date":"2015","source":"Journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/26062860","citation_count":35,"is_preprint":false},{"pmid":"19569052","id":"PMC_19569052","title":"GLUT-1 expression and response to chemoradiotherapy in rectal cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19569052","citation_count":34,"is_preprint":false},{"pmid":"25417118","id":"PMC_25417118","title":"Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25417118","citation_count":34,"is_preprint":false},{"pmid":"29303961","id":"PMC_29303961","title":"Individualizing Treatment Approaches for Epileptic Patients with Glucose Transporter Type1 (GLUT-1) Deficiency.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29303961","citation_count":34,"is_preprint":false},{"pmid":"13129590","id":"PMC_13129590","title":"Glucose transporter type1 (GLUT-1) deficiency.","date":"2003","source":"Brain & development","url":"https://pubmed.ncbi.nlm.nih.gov/13129590","citation_count":33,"is_preprint":false},{"pmid":"11546675","id":"PMC_11546675","title":"Stimulation of GLUT-1 glucose transporter expression in response to hyperosmolarity.","date":"2001","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/11546675","citation_count":32,"is_preprint":false},{"pmid":"29404819","id":"PMC_29404819","title":"Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma.","date":"2018","source":"Annals of surgical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29404819","citation_count":31,"is_preprint":false},{"pmid":"29797802","id":"PMC_29797802","title":"Glucose transporter-1 (GLUT-1) expression in psoriasis: correlation with disease severity.","date":"2018","source":"International journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/29797802","citation_count":30,"is_preprint":false},{"pmid":"16391802","id":"PMC_16391802","title":"Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma.","date":"2006","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16391802","citation_count":30,"is_preprint":false},{"pmid":"23980682","id":"PMC_23980682","title":"Anticancer mechanism of apigenin and the implications of GLUT-1 expression in head and neck cancers.","date":"2013","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23980682","citation_count":30,"is_preprint":false},{"pmid":"22492876","id":"PMC_22492876","title":"An infant with pseudohyperkalemia, hemolysis, and seizures: cation-leaky GLUT1-deficiency syndrome due to a SLC2A1 mutation.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22492876","citation_count":30,"is_preprint":false},{"pmid":"19318800","id":"PMC_19318800","title":"INI1 and GLUT-1 expression in epithelioid sarcoma and its cutaneous neoplastic and nonneoplastic mimics.","date":"2009","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/19318800","citation_count":29,"is_preprint":false},{"pmid":"12066193","id":"PMC_12066193","title":"Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma.","date":"2002","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/12066193","citation_count":29,"is_preprint":false},{"pmid":"35596882","id":"PMC_35596882","title":"Therapeutic implications of glucose transporters (GLUT) in cerebral ischemia.","date":"2022","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/35596882","citation_count":28,"is_preprint":false},{"pmid":"16515729","id":"PMC_16515729","title":"Role for GLUT1 in diabetic glomerulosclerosis.","date":"2006","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16515729","citation_count":28,"is_preprint":false},{"pmid":"23340081","id":"PMC_23340081","title":"The many faces of Glut1 deficiency syndrome.","date":"2013","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23340081","citation_count":28,"is_preprint":false},{"pmid":"35415942","id":"PMC_35415942","title":"Effect of Glut-1 and HIF-1α double knockout by CRISPR/CAS9 on radiosensitivity in laryngeal carcinoma via the PI3K/Akt/mTOR pathway.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35415942","citation_count":28,"is_preprint":false},{"pmid":"8572196","id":"PMC_8572196","title":"Regulation of glucose transport and GLUT-1 expression by iron chelators in muscle cells in culture.","date":"1995","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8572196","citation_count":28,"is_preprint":false},{"pmid":"34555239","id":"PMC_34555239","title":"Placental expression of glucose transporters GLUT-1, GLUT-3, GLUT-8 and GLUT-12 in pregnancies complicated by gestational and type 1 diabetes mellitus.","date":"2021","source":"Journal of diabetes investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34555239","citation_count":28,"is_preprint":false},{"pmid":"36068393","id":"PMC_36068393","title":"Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma.","date":"2022","source":"Journal of natural medicines","url":"https://pubmed.ncbi.nlm.nih.gov/36068393","citation_count":27,"is_preprint":false},{"pmid":"33916948","id":"PMC_33916948","title":"Oxidative Stress-Induced Sirtuin1 Downregulation Correlates to HIF-1α, GLUT-1, and VEGF-A Upregulation in Th1 Autoimmune Hashimoto's Thyroiditis.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33916948","citation_count":27,"is_preprint":false},{"pmid":"30480843","id":"PMC_30480843","title":"Membrane-enriched solute carrier family 2 member 1 (SLC2A1/GLUT1) in psoriatic keratinocytes confers sensitivity to 2-deoxy-D-glucose (2-DG) treatment.","date":"2018","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30480843","citation_count":26,"is_preprint":false},{"pmid":"2100513","id":"PMC_2100513","title":"Vanadate regulates glucose transporter (Glut-1) expression in NIH3T3 mouse fibroblasts.","date":"1990","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/2100513","citation_count":26,"is_preprint":false},{"pmid":"34580846","id":"PMC_34580846","title":"GLUT-1 Expression in Breast Cancer.","date":"2022","source":"Turk patoloji dergisi","url":"https://pubmed.ncbi.nlm.nih.gov/34580846","citation_count":25,"is_preprint":false},{"pmid":"33580997","id":"PMC_33580997","title":"TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation.","date":"2021","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33580997","citation_count":25,"is_preprint":false},{"pmid":"36739076","id":"PMC_36739076","title":"Characterization of the effect of the GLUT-1 inhibitor BAY-876 on T cells and macrophages.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36739076","citation_count":25,"is_preprint":false},{"pmid":"34517880","id":"PMC_34517880","title":"Long non-coding RNA SLC2A1-AS1 induced by GLI3 promotes aerobic glycolysis and progression in esophageal squamous cell carcinoma by sponging miR-378a-3p to enhance Glut1 expression.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34517880","citation_count":25,"is_preprint":false},{"pmid":"11189940","id":"PMC_11189940","title":"Correlation of Glut-1 glucose transporter expression with.","date":"2000","source":"European journal of nuclear medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11189940","citation_count":23,"is_preprint":false},{"pmid":"27020375","id":"PMC_27020375","title":"Immunohistochemical Expression of GLUT-1 and HIF-1α in Tooth Germ, Ameloblastoma, and Ameloblastic Carcinoma.","date":"2016","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27020375","citation_count":23,"is_preprint":false},{"pmid":"24824604","id":"PMC_24824604","title":"A novel SLC2A1 mutation linking hemiplegic migraine with alternating hemiplegia of childhood.","date":"2014","source":"Cephalalgia : an international journal of headache","url":"https://pubmed.ncbi.nlm.nih.gov/24824604","citation_count":23,"is_preprint":false},{"pmid":"37175477","id":"PMC_37175477","title":"Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37175477","citation_count":22,"is_preprint":false},{"pmid":"26092229","id":"PMC_26092229","title":"GLUT-1 Expression in Cutaneous Basal and Squamous Cell Carcinomas.","date":"2015","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26092229","citation_count":21,"is_preprint":false},{"pmid":"27902598","id":"PMC_27902598","title":"Correlation of Glut-1 and Glut-3 expression with F-18 FDG uptake in pulmonary inflammatory lesions.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27902598","citation_count":21,"is_preprint":false},{"pmid":"29128957","id":"PMC_29128957","title":"Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/29128957","citation_count":20,"is_preprint":false},{"pmid":"16785788","id":"PMC_16785788","title":"GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.","date":"2006","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/16785788","citation_count":20,"is_preprint":false},{"pmid":"28542798","id":"PMC_28542798","title":"GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28542798","citation_count":20,"is_preprint":false},{"pmid":"35357376","id":"PMC_35357376","title":"Antihyperglycemic effect of an anthocyanin, cyanidin-3-O-glucoside, is achieved by regulating GLUT-1 via the Wnt/β-catenin-WISP1 signaling pathway.","date":"2022","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/35357376","citation_count":19,"is_preprint":false},{"pmid":"32180291","id":"PMC_32180291","title":"Gene and immunohistochemical expression of HIF-1α, GLUT-1, FASN, and adipophilin in carcinoma ex pleomorphic adenoma development.","date":"2020","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32180291","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52653,"output_tokens":6385,"usd":0.126867,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15319,"output_tokens":6863,"usd":0.124085,"stage2_stop_reason":"end_turn"},"total_usd":0.250952,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"GLUT-1 (SLC2A1) is a functional receptor for both HTLV-1 and HTLV-2. The receptor-binding domains of HTLV-1 and HTLV-2 envelope glycoproteins interact with GLUT-1 and inhibit glucose transport. siRNA knockdown of GLUT-1 abrogated HTLV infection, and ectopic expression of GLUT-1 (but not the related GLUT-3) restored infection in GLUT-1-depleted cells.\",\n      \"method\": \"siRNA knockdown, ectopic overexpression, glucose transport inhibition assay, HTLV envelope-driven infection assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — reciprocal functional rescue experiments, siRNA knockdown, and overexpression with multiple orthogonal readouts in a single rigorous study\",\n      \"pmids\": [\"14622599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Stomatin (band 7.2b) physically associates with GLUT-1 at the C-terminal 42-amino acid segment of GLUT-1, and overexpression of stomatin reduces GLUT-1 intrinsic transport activity by 35–70% without altering GLUT-1 plasma membrane content, demonstrating that stomatin modulates GLUT-1 activity via protein–protein interaction.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown with GLUT-1 C-terminal fusion protein, stable transfection, glucose transport assay\",\n      \"journal\": \"American Journal of Physiology. Cell Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, GST pulldown mapping to specific GLUT-1 domain, and functional transport assay in a single study\",\n      \"pmids\": [\"11287341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In human erythrocyte membranes, in situ chemical cross-linking followed by immunoaffinity purification and mass spectrometry identified stomatin, band 3/SLC4A1, and aquaporin-1 as direct interaction partners of GLUT-1, establishing GLUT-1 as a component of a multiprotein membrane complex.\",\n      \"method\": \"In situ chemical cross-linking, immunoaffinity chromatography, mass spectrometry\",\n      \"journal\": \"Biochimica et Biophysica Acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in situ cross-linking with mass spectrometry identification, single lab but multiple orthogonal biochemical methods\",\n      \"pmids\": [\"23219802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GLUT-1 interacts with the ER chaperone calnexin (and its soluble homologue calreticulin) in a glycosylation-dependent manner during folding in the endoplasmic reticulum; a non-glycosylated GLUT-1 mutant (AGGT155) failed to associate with either calnexin or calreticulin.\",\n      \"method\": \"In vitro translation in rabbit reticulocyte lysate with canine pancreatic microsomes, co-immunoprecipitation with anti-calnexin antiserum, UV cross-linking, glycosylation mutant analysis\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with microsomes, UV cross-linking, and glycosylation mutant controls in a single study\",\n      \"pmids\": [\"8662691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ATM kinase phosphorylates GLUT-1 at serine 490 (S490), and this phosphorylation promotes cell-surface localization of GLUT-1, its interaction with GIPC1 (a recycling endosome protein), and GLUT-1-mediated glucose and dehydroascorbic acid transport in skeletal muscle cells. S490A mutation decreased transport and surface GLUT-1, while S490D mutation increased both.\",\n      \"method\": \"ATM inhibitor treatment, doxorubicin-mediated ATM activation, S490A and S490D point mutants, cell-surface GLUT-1 measurement, glucose and DHA transport assays, Co-IP of GLUT-1/GIPC1, mouse skeletal muscle ex vivo transport assay\",\n      \"journal\": \"PloS One\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mutagenesis of the phosphorylation site, pharmacological ATM modulation, functional transport assays, and Co-IP, replicated in cells and mouse tissue\",\n      \"pmids\": [\"23776597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"RAB21 GTPase regulates retromer-mediated recycling of GLUT-1/SLC2A1: RAB21 depletion mis-sorts GLUT-1 to lysosomes, reducing glucose uptake and thereby activating the AMPK-ULK1 autophagy pathway. RAB21 depletion also caused accumulation of the SNX27-containing retromer complex on enlarged endosomes, indicating RAB21 regulates endosomal tubule fission during GLUT-1 recycling.\",\n      \"method\": \"siRNA knockdown of RAB21, subcellular localization by microscopy, glucose uptake assay, AMPK-ULK1 pathway analysis, immunofluorescence of retromer/SNX27, in vivo tumor xenograft\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined subcellular trafficking phenotype and functional metabolic readout, single lab\",\n      \"pmids\": [\"35993307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Insulin- and TSH-induced translocation of GLUT-1 from intracellular compartments to the plasma membrane in FRTL-5 thyroid cells is dependent on PI3-kinase activity (blocked by wortmannin and LY294002). TSH/cAMP-driven translocation occurs via a PKA-independent, PI3-kinase-dependent pathway. N-glycosylation of GLUT-1 is required for full transport activity but not for its translocation to the plasma membrane.\",\n      \"method\": \"PI3-kinase inhibitors (wortmannin, LY294002), PKA inhibitor (H89), tunicamycin (N-glycosylation inhibitor), subcellular fractionation, glucose uptake assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with multiple inhibitors and functional translocation/transport readouts, single lab\",\n      \"pmids\": [\"11089547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In mesangial cells, GLUT-1 transcription is stimulated by high D-glucose in a manner dependent on glucose metabolism (not the hexose monophosphate shunt). Antisense-mediated reduction of GLUT-1 expression blocks high-glucose-induced upregulation of GLUT-1 and fibronectin expression, demonstrating that GLUT-1-mediated glucose uptake drives a feed-forward loop promoting extracellular matrix production.\",\n      \"method\": \"Stable antisense GLUT-1 transfection, radiolabeled glucose uptake, GLUT-1 transcription assay, fibronectin mRNA and protein measurement, metabolic substrate substitution experiments\",\n      \"journal\": \"American Journal of Physiology. Renal Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined molecular readout, multiple substrates tested, single lab\",\n      \"pmids\": [\"11249857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The transcription factor Sp1 binds the −102/−82 region of the GLUT-1 promoter and is essential for high transcriptional activity in fetal/neonatal cardiomyocytes; Sp1 is markedly downregulated perinatally in heart and skeletal muscle, explaining the developmental repression of GLUT-1 transcription.\",\n      \"method\": \"Transient transfection reporter assays, electrophoretic mobility shift assay (EMSA), Sp1 site mutagenesis, developmental Western blot\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — EMSA with site mutagenesis and functional reporter assay, consistent with in vivo developmental expression pattern\",\n      \"pmids\": [\"10364200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Hyperosmolarity (600 mosmol/L) induces a biphasic increase in GLUT-1-mediated glucose transport: an early phase (0–6 h) independent of changes in GLUT-1 mRNA or protein, and a late phase (12–24 h) driven by increased GLUT-1 mRNA (via both enhanced transcription and mRNA stabilization, half-life increasing from ~2 h to ~8 h) and increased GLUT-1 protein. A 44-bp proximal promoter region is required for basal and hyperosmolarity-induced transcription.\",\n      \"method\": \"mRNA stability assay, promoter deletion/reporter assay, glucose transport assay, Western blot, GLUT-1 plasma membrane fractionation\",\n      \"journal\": \"American Journal of Physiology. Cell Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional promoter dissection, mRNA stability measurement, and transport assay, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"11546675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"Vanadate increases GLUT-1 mRNA expression 4–5-fold in NIH3T3 fibroblasts partly through mRNA stabilization (half-life increased from ~0.5–1 h to ~1.5–2 h), indicating a post-transcriptional regulatory mechanism for GLUT-1 expression.\",\n      \"method\": \"Northern blot, mRNA half-life determination with actinomycin D chase, glucose transporter functional assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mRNA stability assay with single method, single lab\",\n      \"pmids\": [\"2100513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Heterozygous missense, deletion, insertion, splice-site, and nonsense mutations in GLUT-1/SLC2A1 cause Glut-1 Deficiency Syndrome, characterized by reduced erythrocyte glucose transport activity and hypoglycorrhachia, confirming that GLUT-1 is the essential blood-brain barrier hexose transporter and that single-allele loss is sufficient to impair CNS glucose delivery.\",\n      \"method\": \"FISH, PCR, SSCP, DNA sequencing, erythrocyte glucose transport activity assay\",\n      \"journal\": \"Human Mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional transport assay correlated with 15 independent pathogenic mutations, multiple mutation classes, replicated across patients\",\n      \"pmids\": [\"10980529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Heterozygous targeted disruption of the mouse GLUT-1 gene produces haploinsufficiency phenotype: 66% reduction in brain GLUT-1 protein, reduced brain glucose uptake by PET, hypoglycorrhachia, microencephaly, epileptiform EEG discharges, and impaired motor activity — directly demonstrating that GLUT-1 is the critical blood-brain barrier glucose transporter in vivo.\",\n      \"method\": \"Targeted gene disruption (homologous recombination), PET imaging, EEG, Western blot, behavioral assays, CSF glucose measurement\",\n      \"journal\": \"Human Molecular Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — constitutive KO mouse with multiple orthogonal in vivo phenotypic readouts mirroring human disease\",\n      \"pmids\": [\"16497725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In vivo knockdown of Glut1 in zebrafish causes loss of cerebral endothelial cells, downregulation of adherens and tight junction proteins, impaired cerebral circulation, and vasogenic brain edema, demonstrating that Glut1 is required for blood-brain barrier development and maintenance of cerebrovascular integrity.\",\n      \"method\": \"Morpholino-based Glut1 knockdown in zebrafish, live fluorescence imaging, junction protein immunostaining, BBB permeability assay\",\n      \"journal\": \"Annals of Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD in zebrafish with defined vascular and molecular phenotypes, single lab\",\n      \"pmids\": [\"21194153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mutations in SLC2A1 cause paroxysmal choreoathetosis/spasticity (DYT9), and DYT9 is allelic with DYT18 (paroxysmal exercise-induced dyskinesia); identified mutations reduce glucose uptake in functional assays, confirming causality and expanding the clinical spectrum of GLUT-1 deficiency.\",\n      \"method\": \"SLC2A1 sequencing, glucose uptake functional assay, cosegregation analysis, absence from 400 control chromosomes\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional glucose uptake assay correlated with mutations in two independent pedigrees, replicated across families\",\n      \"pmids\": [\"21832227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Myeloid-specific deletion of Slc2a1 (GLUT1) in macrophages blocks glucose uptake and glycolysis, forces metabolic compensation via glutamine and oleate oxidation, blunts maximal respiratory capacity, reduces proinflammatory metabolites, elevates alternative-activation markers (ornithine, polyamines, CD206), and impairs phagocytic capacity — demonstrating that GLUT1 fuels macrophage glycolysis and is required for normal phagocytosis and inflammatory metabolic programming.\",\n      \"method\": \"Myeloid-specific Cre-lox Slc2a1 knockout, glucose uptake assay, Seahorse metabolic flux analysis, flow cytometry, cytokine measurement, phagocytosis assay, atherosclerosis model\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — cell-type-specific KO mouse with multiple orthogonal metabolic and functional readouts in vitro and in vivo\",\n      \"pmids\": [\"30659108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"GLUT-1 overexpression in vascular smooth muscle cells reduces hypoxia-induced apoptosis and markedly attenuates hypoxia- and rotenone-induced JNK kinase activation; a catalytically inactive MEKK1 mutant partially phenocopied this protection, placing GLUT-1-dependent glucose uptake upstream of the JNK stress-kinase apoptosis pathway.\",\n      \"method\": \"Stable GLUT-1 overexpression, hypoxia and rotenone treatment, apoptosis morphology quantification, JNK activity assay, dominant-negative MEKK1 transfection\",\n      \"journal\": \"American Journal of Physiology. Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via dominant-negative kinase and GLUT-1 overexpression with defined biochemical pathway readout, single lab\",\n      \"pmids\": [\"10780954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GLUT-1/SLC2A1 expression is upregulated by hypoxia via HIF-1α stabilization in brain capillary endothelial cells, accompanied by increased [3H]-glucose uptake; stabilizing HIF-1α pharmacologically with desferrioxamine under normoxia mimics this effect, establishing HIF-1α as the transcriptional regulator of GLUT-1 upregulation in BBB endothelium under hypoxia.\",\n      \"method\": \"Primary bovine brain capillary endothelial cell culture under hypoxia, HIF-1α immunocytochemistry/confocal imaging, qPCR, Western blot, [3H]-glucose uptake assay, desferrioxamine (DFO) pharmacological HIF-1α stabilization\",\n      \"journal\": \"Fluids and Barriers of the CNS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological HIF-1α stabilization mimicking hypoxia with functional transport readout, single lab, multiple methods\",\n      \"pmids\": [\"34983574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-328 directly targets the 3′-UTR of SLC2A1/GLUT1 mRNA (confirmed by luciferase reporter assay) and suppresses GLUT1 protein expression in colon cancer cells, reducing glycolysis.\",\n      \"method\": \"Luciferase reporter assay with SLC2A1 3′-UTR, Western blot, miR-328 overexpression in colon cancer cell lines\",\n      \"journal\": \"Clinical & Translational Oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter and Western blot confirmation, single lab, two cell lines\",\n      \"pmids\": [\"29374351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-148b directly targets SLC2A1/GLUT1 3′-UTR (luciferase assay), suppresses GLUT1 protein, and limits glycolysis (glucose consumption, lactate production) in gastric cancer cells; GLUT1 overexpression rescued glycolysis suppressed by miR-148b, establishing direct miR-148b → GLUT1 → glycolysis regulation.\",\n      \"method\": \"Luciferase 3′-UTR reporter assay, Western blot, siRNA, GLUT1 overexpression rescue, glucose/lactate metabolic assays\",\n      \"journal\": \"Cancer Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase, rescue experiment, and functional metabolic assay, single lab\",\n      \"pmids\": [\"28440026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Isoginkgetin (ISO) suppresses SLC2A1/GLUT1 enhancer activity (reducing H3K27ac, H4K8ac, and H3K4me1 marks on the GLUT1 enhancer) by binding to and promoting degradation of CDK6; CDK6 overexpression rescued GLUT1 transcription and autophagy suppression, placing CDK6 upstream of GLUT1 enhancer activity in HCC.\",\n      \"method\": \"Molecular docking, thermal shift analysis, CDK6 overexpression rescue, ChIP for histone marks at SLC2A1 enhancer, glucose uptake assay, AMPK-ULK1 pathway analysis, xenograft\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct CDK6 binding confirmed by thermal shift, ChIP mapping to GLUT1 enhancer, genetic rescue, single lab\",\n      \"pmids\": [\"36048765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Transgenic overexpression of GLUT-1 in skeletal muscle paradoxically reduces insulin-stimulated whole-body glucose disposal (GIR 54% of controls) and induces marked hyperketonemia, whereas GLUT-4 overexpression enhances insulin-stimulated glucose disposal — demonstrating that the identity (not merely level) of glucose transporter isoform critically shapes whole-body insulin responsiveness.\",\n      \"method\": \"Euglycemic hyperinsulinemic clamp in transgenic mice overexpressing GLUT-1 or GLUT-4, glucose infusion rate measurement, β-hydroxybutyrate measurement\",\n      \"journal\": \"The American Journal of Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo metabolic clamp in two independent transgenic mouse lines with direct comparison of GLUT-1 vs GLUT-4 isoform-specific effects\",\n      \"pmids\": [\"7977725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SLC2A1 trinucleotide deletion (deleting isoleucine 435 or 436) causes a cation-leaky GLUT-1 variant that constitutively allows monovalent cation (Na+/K+) permeation across the red cell membrane, in addition to abrogating glucose transport — demonstrating that single residues in the GLUT-1 transmembrane domain determine both substrate selectivity and cation permeability.\",\n      \"method\": \"SLC2A1 sequencing, red cell cation content measurement, temperature-dependent K+ loss assay, clinical phenotyping\",\n      \"journal\": \"The Journal of Clinical Endocrinology and Metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — functional red cell transport assay with identified mutation, single case/family\",\n      \"pmids\": [\"22492876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GLUT-1/SLC2A1 siRNA intravitreal injection in diabetic mice reduces retinal glucose concentration, ICAM-1 and TNF-α expression, leukostasis, and vascular leakage — establishing that GLUT-1-mediated glucose transport into the retina is a causal driver of the inflammatory microangiopathy of diabetic retinopathy.\",\n      \"method\": \"Intravitreal siRNA injection in streptozotocin-diabetic mice, retinal glucose assay, ERG, immunoblotting for ICAM-1/TNF-α, leukostasis assay, Evans blue vascular permeability assay\",\n      \"journal\": \"Scientific Reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo siRNA KD with multiple mechanistic readouts, single lab\",\n      \"pmids\": [\"28785055\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SLC2A1/GLUT-1 is a 12-transmembrane-domain facilitative glucose transporter that mediates constitutive glucose uptake across the plasma membrane; its transport activity is modulated by stomatin (via direct C-terminal protein–protein interaction), by ATM-mediated phosphorylation at S490 (which promotes surface localization via GIPC1-dependent recycling), and by retromer/RAB21-dependent endosomal recycling; its transcription is driven by Sp1 in cardiomyocytes and by HIF-1α under hypoxia, and its mRNA is stabilized by osmotic and metabolic stress; it serves as the obligate HTLV receptor, is essential for blood-brain barrier development and glucose delivery to the CNS (haploinsufficiency causing seizures, hypoglycorrhachia, and microcephaly), and fuels macrophage glycolysis required for normal phagocytic and inflammatory function.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SLC2A1/GLUT-1 is the constitutive facilitative glucose transporter that delivers glucose across the plasma membrane to fuel cellular metabolism, and it is the obligate hexose transporter of the blood-brain barrier [#11, #12]. Its substrate selectivity and cation impermeability are determined by individual transmembrane residues, with isoleucine deletions in the transmembrane domain both abrogating glucose transport and creating a cation-leaky channel [#22]. Transport activity is set not only by surface abundance but by direct protein-protein modulation: stomatin binds the GLUT-1 C-terminal 42-residue segment and suppresses intrinsic transport activity without changing membrane content, and GLUT-1 functions within a multiprotein erythrocyte membrane complex with stomatin, band 3/SLC4A1, and aquaporin-1 [#1, #2]. Surface delivery is governed by trafficking: N-glycosylation-dependent folding under calnexin/calreticulin in the ER [#3], PI3-kinase-dependent insulin/TSH-induced translocation [#6], ATM-mediated phosphorylation at S490 that drives GIPC1-dependent recycling endosome surface localization [#4], and RAB21/retromer-dependent endosomal recycling that prevents lysosomal mis-sorting and thereby restrains AMPK-ULK1 autophagy [#5]. GLUT-1 transcription is driven by Sp1 in developing cardiomyocytes [#8] and by HIF-1\\u03b1 under hypoxia [#17], while its mRNA is stabilized by osmotic and metabolic stress [#9, #10] and repressed post-transcriptionally by microRNAs targeting its 3'-UTR [#18, #19]. Functionally, GLUT-1-mediated glucose uptake fuels macrophage glycolysis required for phagocytosis and inflammatory metabolic programming [#15], drives feed-forward extracellular matrix production in mesangial cells [#7], and protects against hypoxic apoptosis upstream of JNK stress signaling [#16]. Heterozygous loss-of-function mutations cause GLUT-1 Deficiency Syndrome with hypoglycorrhachia, seizures, and microcephaly, and allelic mutations cause paroxysmal exercise-induced dyskinesia (DYT9/DYT18) [#11, #14]. GLUT-1 also serves as the functional receptor for HTLV-1 and HTLV-2 [#0].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established that GLUT-1 expression is regulated post-transcriptionally, addressing whether transporter abundance is controlled beyond transcription.\",\n      \"evidence\": \"Vanadate-induced mRNA half-life measurement by actinomycin D chase and Northern blot in NIH3T3 fibroblasts\",\n      \"pmids\": [\"2100513\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The trans-acting factor or 3'-UTR element mediating stabilization was not identified\", \"Single stimulus and single cell type\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showed that glucose transporter isoform identity, not just transport capacity, shapes whole-body insulin responsiveness, distinguishing GLUT-1 from insulin-responsive GLUT-4.\",\n      \"evidence\": \"Euglycemic hyperinsulinemic clamp in transgenic mice overexpressing GLUT-1 versus GLUT-4 in skeletal muscle\",\n      \"pmids\": [\"7977725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism for paradoxical reduction in insulin-stimulated disposal and hyperketonemia not resolved\", \"Does not address endogenous GLUT-1 physiology\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defined the biogenesis route of GLUT-1, showing glycosylation-dependent ER chaperone engagement governs folding before surface delivery.\",\n      \"evidence\": \"In vitro translation with pancreatic microsomes, anti-calnexin Co-IP, UV cross-linking, and a non-glycosylated AGGT155 mutant\",\n      \"pmids\": [\"8662691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream quality-control fate of misfolded GLUT-1 not characterized\", \"In vitro reconstitution only\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified Sp1 as the transcriptional driver of GLUT-1 in heart and linked perinatal Sp1 loss to developmental repression of the gene.\",\n      \"evidence\": \"Reporter assays, EMSA with Sp1 site mutagenesis, and developmental Western blot in cardiomyocytes\",\n      \"pmids\": [\"10364200\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors at the Sp1 site not defined\", \"Restricted to cardiac/skeletal muscle context\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved the signaling route for stimulus-induced GLUT-1 surface translocation, showing it is PI3-kinase-dependent and PKA-independent.\",\n      \"evidence\": \"Pharmacological dissection with wortmannin, LY294002, H89, and tunicamycin plus subcellular fractionation in FRTL-5 thyroid cells\",\n      \"pmids\": [\"11089547\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Vesicle machinery downstream of PI3K not identified\", \"Pharmacological inhibitors lack target specificity\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Confirmed in vivo that single-allele GLUT-1 mutations are sufficient to impair CNS glucose delivery, establishing GLUT-1 as the essential blood-brain barrier hexose transporter and defining GLUT-1 Deficiency Syndrome.\",\n      \"evidence\": \"Mutation screening across multiple patients correlated with erythrocyte glucose transport assays\",\n      \"pmids\": [\"10980529\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype severity correlation not fully resolved\", \"Does not address tissue-specific dosage thresholds\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placed GLUT-1-dependent glucose uptake upstream of the JNK stress-kinase apoptosis pathway, linking the transporter to cell survival under hypoxia.\",\n      \"evidence\": \"GLUT-1 overexpression with hypoxia/rotenone challenge, JNK activity assay, and dominant-negative MEKK1 epistasis in vascular smooth muscle cells\",\n      \"pmids\": [\"10780954\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Metabolic signal connecting glucose uptake to JNK suppression not defined\", \"Overexpression rather than endogenous regulation\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated direct protein-protein modulation of GLUT-1 transport activity by stomatin, independent of surface abundance.\",\n      \"evidence\": \"Co-IP, GST pulldown mapping to the GLUT-1 C-terminal 42 residues, and glucose transport assay in transfected cells\",\n      \"pmids\": [\"11287341\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the C-terminal interaction not solved\", \"Mechanism by which binding lowers intrinsic activity unknown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed GLUT-1-mediated glucose uptake drives a feed-forward loop promoting extracellular matrix production, linking the transporter to diabetic glomerular pathology.\",\n      \"evidence\": \"Antisense GLUT-1 knockdown with fibronectin readout and metabolic substrate substitution in mesangial cells\",\n      \"pmids\": [\"11249857\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Metabolic signal coupling glucose flux to fibronectin transcription not identified\", \"Single cell type\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined a biphasic GLUT-1 response to osmotic stress combining transcriptional induction and mRNA stabilization, mapping a 44-bp proximal promoter element.\",\n      \"evidence\": \"mRNA stability assay, promoter deletion reporters, transport assay, and membrane fractionation under hyperosmolarity\",\n      \"pmids\": [\"11546675\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The factor mediating mRNA stabilization not identified\", \"Early phase mechanism (non-transcriptional, non-translocation) unexplained\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified GLUT-1 as the obligate functional receptor for HTLV-1 and HTLV-2, with envelope binding directly inhibiting glucose transport.\",\n      \"evidence\": \"siRNA knockdown, ectopic GLUT-1 versus GLUT-3 rescue, glucose transport inhibition, and infection assays\",\n      \"pmids\": [\"14622599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The GLUT-1 binding interface for envelope glycoprotein not mapped\", \"Whether transport inhibition is mechanistically required for entry not resolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Recapitulated GLUT-1 Deficiency Syndrome in vivo, directly demonstrating that GLUT-1 haploinsufficiency reduces brain glucose uptake and causes the seizure/microcephaly phenotype.\",\n      \"evidence\": \"Heterozygous GLUT-1 knockout mouse with PET, EEG, CSF glucose, Western blot, and behavioral assays\",\n      \"pmids\": [\"16497725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular site of critical dosage sensitivity (endothelium vs glia vs neuron) not isolated\", \"Developmental timing of irreversible injury not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established a developmental and structural role for GLUT-1 in blood-brain barrier formation beyond simple glucose delivery, showing it is required for cerebral endothelial integrity.\",\n      \"evidence\": \"Morpholino Glut1 knockdown in zebrafish with junction protein immunostaining and BBB permeability assays\",\n      \"pmids\": [\"21194153\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the vascular defect is secondary to metabolic deficit or a distinct function unclear\", \"Morpholino off-target effects not fully excluded\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Expanded the GLUT-1 deficiency phenotypic spectrum to paroxysmal dyskinesia, showing DYT9 is allelic with DYT18 and that the mutations reduce glucose uptake.\",\n      \"evidence\": \"SLC2A1 sequencing, cosegregation, control screening, and glucose uptake functional assays in two pedigrees\",\n      \"pmids\": [\"21832227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why partial loss yields paroxysmal rather than constant phenotype not explained\", \"Genotype-phenotype determinants across the spectrum unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the native GLUT-1 membrane complex partners in erythrocytes, situating the transporter within a multiprotein assembly.\",\n      \"evidence\": \"In situ chemical cross-linking, immunoaffinity purification, and mass spectrometry of erythrocyte membranes\",\n      \"pmids\": [\"23219802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of band 3 and aquaporin-1 association not tested\", \"Stoichiometry and architecture of the complex unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed that single transmembrane residues govern both glucose selectivity and cation impermeability, as an isoleucine deletion creates a cation-leaky GLUT-1.\",\n      \"evidence\": \"SLC2A1 sequencing with red cell cation content and temperature-dependent K+ loss assays\",\n      \"pmids\": [\"22492876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single family; structural mechanism of the cation leak not modeled\", \"Relationship between leak and clinical phenotype not fully defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified ATM-mediated S490 phosphorylation as a regulatory switch driving GLUT-1 surface localization through GIPC1-dependent recycling.\",\n      \"evidence\": \"S490A/S490D mutants, pharmacological ATM modulation, GLUT-1/GIPC1 Co-IP, and transport assays in cells and mouse muscle\",\n      \"pmids\": [\"23776597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological signal activating ATM-GLUT-1 phosphorylation in muscle not defined\", \"How GIPC1 engagement directs recycling mechanistically unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated microRNA control of GLUT-1, with miR-148b directly targeting the 3'-UTR to limit glycolysis in cancer cells.\",\n      \"evidence\": \"Luciferase 3'-UTR reporter, Western blot, siRNA, GLUT1 overexpression rescue, and glucose/lactate assays in gastric cancer cells\",\n      \"pmids\": [\"28440026\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of the miR-148b axis not established\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established GLUT-1-mediated retinal glucose transport as a causal driver of diabetic inflammatory microangiopathy.\",\n      \"evidence\": \"Intravitreal GLUT-1 siRNA in diabetic mice with retinal glucose, ICAM-1/TNF-\\u03b1, leukostasis, and vascular permeability readouts\",\n      \"pmids\": [\"28785055\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell type within retina mediating the effect not isolated\", \"Single lab in vivo model\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Added a second microRNA, miR-328, directly repressing GLUT1 via its 3'-UTR to reduce glycolysis in colon cancer.\",\n      \"evidence\": \"Luciferase reporter with SLC2A1 3'-UTR, Western blot, and miR-328 overexpression in colon cancer cell lines\",\n      \"pmids\": [\"29374351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional metabolic rescue not shown as definitively as for miR-148b\", \"No in vivo validation\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined GLUT1 as the essential fuel source for macrophage glycolysis, required for phagocytosis and inflammatory metabolic programming.\",\n      \"evidence\": \"Myeloid-specific Slc2a1 knockout with Seahorse flux, metabolite profiling, flow cytometry, phagocytosis, and atherosclerosis modeling\",\n      \"pmids\": [\"30659108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether glycolytic versus non-metabolic functions drive the phenotype not fully separated\", \"Compensatory glutamine/oleate pathways not therapeutically tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified RAB21-controlled retromer recycling as essential for keeping GLUT-1 at the surface, with disruption mis-sorting it to lysosomes and activating autophagy.\",\n      \"evidence\": \"RAB21 siRNA, microscopy of GLUT-1 and SNX27 retromer, glucose uptake, AMPK-ULK1 analysis, and tumor xenograft\",\n      \"pmids\": [\"35993307\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RAB21-GLUT-1 versus indirect retromer effect not separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established HIF-1\\u03b1 as the transcriptional driver of GLUT-1 induction in blood-brain barrier endothelium under hypoxia.\",\n      \"evidence\": \"Hypoxia and desferrioxamine HIF-1\\u03b1 stabilization in brain capillary endothelial cells with glucose uptake, qPCR, and Western blot\",\n      \"pmids\": [\"34983574\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct HIF-1\\u03b1 occupancy of the SLC2A1 promoter not shown here\", \"Primary culture model only\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked CDK6 to GLUT1 enhancer activity, showing CDK6 maintains active histone marks that drive GLUT1 transcription in hepatocellular carcinoma.\",\n      \"evidence\": \"Isoginkgetin-induced CDK6 degradation, thermal shift binding, CDK6 rescue, ChIP of enhancer histone marks, glucose uptake, and xenograft\",\n      \"pmids\": [\"36048765\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How CDK6 mechanistically promotes enhancer acetylation/methylation not defined\", \"Restricted to HCC context\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse transcriptional (Sp1, HIF-1\\u03b1, CDK6), post-transcriptional (mRNA stabilization, microRNAs), and trafficking (calnexin, PI3K, ATM/GIPC1, RAB21/retromer, stomatin) regulatory layers are integrated to set GLUT-1 surface activity in a given tissue remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model connecting trafficking control to transcriptional control\", \"Structural basis of substrate selectivity and cation gating not resolved in the corpus\", \"Tissue-specific dosage thresholds underlying disease severity not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [11, 12, 14, 22]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 6]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [11, 12, 15]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [15, 7]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [5, 20]}\n    ],\n    \"complexes\": [\"erythrocyte GLUT-1/stomatin/band 3/aquaporin-1 membrane complex\"],\n    \"partners\": [\"STOM\", \"SLC4A1\", \"AQP1\", \"CANX\", \"CALR\", \"GIPC1\", \"RAB21\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}